These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19962477)

  • 21. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia.
    Al-Kindi SG; DeCicco A; Longenecker CT; Dalton J; Simon DI; Zidar DA
    JAMA Cardiol; 2017 Apr; 2(4):451-452. PubMed ID: 28052161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
    Kłosiewicz-Latoszek L; Cybulska B
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II76-80. PubMed ID: 19813341
    [No Abstract]   [Full Text] [Related]  

  • 24. A call for development of comprehensive therapy for dyslipidemia.
    Deshpande NV; Mardikar HM; Deo D
    J Am Coll Cardiol; 2007 Apr; 49(13):1502; author reply 1502-3. PubMed ID: 17397683
    [No Abstract]   [Full Text] [Related]  

  • 25. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease.
    Poussa H; Strandberg TE; Tikkanen I; Kauhanen P; Lepäntalo M
    Scand Cardiovasc J; 2007 Jun; 41(3):138-41. PubMed ID: 17487761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
    Hanssens L; De Hert M; Kalnicka D; van Winkel R; Wampers M; Van Eyck D; Scheen A; Peuskens J
    Int Clin Psychopharmacol; 2007 Jan; 22(1):43-9. PubMed ID: 17159459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
    Polonsky TS; Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):27B-35B. PubMed ID: 18375238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia.
    Caspard H; Chan AK; Walker AM
    Clin Ther; 2005 Oct; 27(10):1639-46. PubMed ID: 16330301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipids, statins and cardiovascular disease.
    Cheifitz R
    Climacteric; 2008 Aug; 11(4):347-8; author reply 348-50. PubMed ID: 18645702
    [No Abstract]   [Full Text] [Related]  

  • 30. Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
    Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):3K-13K; discussion 34K-35K. PubMed ID: 16291008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of dyslipidemia in clinical practice].
    Paragh G; Harangi M
    Orv Hetil; 2006 Mar; 147(9):389-94. PubMed ID: 16619956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Will obesity increase the proportion of children and adolescents recommended for a statin?
    McCrindle BW; Tyrrell PN; Kavey RE
    Circulation; 2013 Nov; 128(19):2162-5. PubMed ID: 24190936
    [No Abstract]   [Full Text] [Related]  

  • 34. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE; Miltersteiner DR; Campos BM
    J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins and diabetes.
    Maki KC; Dicklin MR; Baum SJ
    Cardiol Clin; 2015 May; 33(2):233-43. PubMed ID: 25939296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrates in the treatment of dyslipidemias--time for a reassessment.
    Goldfine AB; Kaul S; Hiatt WR
    N Engl J Med; 2011 Aug; 365(6):481-4. PubMed ID: 21830963
    [No Abstract]   [Full Text] [Related]  

  • 38. MY APPROACH to the Patient With Memory Loss Who Needs a Statin.
    Watson KE; Sallam T
    Trends Cardiovasc Med; 2017 Feb; 27(2):158-159. PubMed ID: 28107839
    [No Abstract]   [Full Text] [Related]  

  • 39. Routine CAC-scoring prior to initiation of statin therapy - a European perspective.
    Mahabadi AA; Nasir K; Rassaf T
    Eur J Prev Cardiol; 2019 Sep; 26(14):1559-1561. PubMed ID: 30913900
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
    Coban E; Afacan B
    Platelets; 2008 Mar; 19(2):111-4. PubMed ID: 17852772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.